Idacta-mab INT-001 represents a exciting clinical method for managing specific oncological malignancies. The antigen-binding protein demonstrates a distinct process of action, specifically binding to CD-38, a membrane https://bookmark-template.com/story28427610/idacta-mab-int-001-a-innovative-antigen-binding-protein-in-progression